CLINICAL TRIALS

Please visit clinicaltrials.gov for detailed information about our ongoing clinical trials.

EPICENTRX CLINICAL TRIALS

ACTIVELY ENROLLING

Study: A Phase 2a Randomized, Parallel Group, Open- Label, Multicenter Study to Assess the Safety and Efficacy of Different Schedules of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Concomitant Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinomas of the Oral Cavity or Oropharynx
Conditions: Head and Neck Carcinoma, Squamous Cell Carcinomas of the Oral Cavity or Oropharynx
Interventions: Drug: RRx-001; Drug: Cisplatin; Radiation Therapy
Collaborator: Drais Pharmaceuticals, Inc.
Link

Study: RRx-001 in Small, Non-small Cell Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens
Conditions: Small Cell Lung Carcinoma;Carcinoma, Non-Small-Cell Lung, Ovarian Cancer; Neuroendocrine Tumors
Interventions: Drug: RRx-001; Drug: Cisplatin/carboplatin plus albumin (nab-paclitaxel or Abraxane); Drug: cisplatin/carboplatin plus etoposide
Link

Study: Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas
Conditions: Glioblastoma and Anaplastic Gliomas
Interventions: RRx-001 + Radiation + Temozolomide
Link

 

ACTIVE NOT YET ENROLLING

Study: REPLATINUM: A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially with a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Carcinoma
Conditions: Small Cell Carcinoma
Interventions: Drug: RRx-001; Drug: Cisplatin/carboplatin
Link